Antibodies against high‐risk human papillomavirus proteins as markers for noncervical HPV‐related cancers in a Black South African population, according to HIV status

Author:

Singini Mwiza Gideon12,Muchengeti Mazvita234ORCID,Sitas Freddy56,Chen Wenlong Carl278,Combes Jean‐Damien1,Waterboer Tim9,Clifford Gary M.1ORCID

Affiliation:

1. International Agency for Research on Cancer (IARC/WHO) Early Detection, Prevention and Infections Branch Lyon France

2. National Cancer Registry National Institute for Communicable Diseases a Division of the National Health Laboratory Service Johannesburg South Africa

3. School of Public Health University of the Witwatersrand Johannesburg South Africa

4. South African DSI‐NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) Stellenbosch University Stellenbosch South Africa

5. Center for Primary Health Care and Equity, School of Population Health University of New South Wales Sydney Sydney New South Wales Australia

6. Menzies Center of Health Policy, School of Public Health University of Sydney Sydney New South Wales Australia

7. Strengthening Oncology Services Research Unit, Faculty of Health Sciences University of the Witwatersrand Johannesburg South Africa

8. Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences University of the Witwatersrand Johannesburg South Africa

9. Infections and Cancer Epidemiology Division German Cancer Research Center (DKFZ) Heidelberg Germany

Abstract

AbstractHuman papillomavirus (HPV) proteins may elicit antibody responses in the process toward HPV‐related malignancy. However, HPV seroepidemiology in noncervical HPV‐related cancers remains poorly understood, particularly in populations with a high prevalence of human immunodeficiency virus (HIV). Using a glutathione S‐transferase‐based multiplex serology assay, antibodies against E6, E7 and L1 proteins of HPV16 and HPV18 were measured in sera of 535 cases of noncervical HPV‐related cancers (anal (n = 104), vulval (n = 211), vaginal (n = 49), penile (n = 37) and oropharyngeal (n = 134)) and 6651 non‐infection‐related cancer controls, from the Johannesburg Cancer Study that recruited Black South African with newly diagnosed cancer between 1995 and 2016. Logistic and Poisson regression models were used to calculate adjusted odds ratios (aOR) and prevalence ratios (aPR) and 95% confidence intervals (CI) in cases versus controls. HPV16 E6 was more strongly associated with noncervical HPV‐related cancers than HPV16 L1 or E7, or HPV18 proteins: anal (females (HPV16 E6 aOR = 11.50;95%CI:6.0–22.2), males (aOR = 10.12;95%CI:4.9–20.8), vulval (aOR = 11.69;95%CI:7.9–17.2), vaginal (aOR = 10.26;95%CI:5.0–21), penile (aOR = 18.95;95%CI:8.9–40), and oropharyngeal (females (aOR = 8.95;95%CI:2.9–27.5), males (aOR = 3.49;95%CI:1.8–7.0)) cancers. HPV16‐E6 seropositivity ranged from 24.0% to 35.1% in anal, vulval, vaginal and penile cancer but was significantly lower (11.2%) in oropharyngeal cancer. After adjustment for HIV, prevalence of which increased from 22.2% in 1995–2005 to 54.1% in 2010–2016, HPV16 E6 seropositivity increased by period of diagnosis (aPR for 2010–2016 vs. 1995–2006 = 1.84;95%CI:1.1–3.0). Assuming HPV16 E6 seroprevalence reflects HPV attributable fraction, the proportion of certain noncervical‐HPV‐related cancers caused by HPV is increasing over time in South Africa. This is expected to be driven by the increasing influence of HIV.

Funder

Centre International de Recherche sur le Cancer

Publisher

Wiley

Reference44 articles.

1. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis

2. Worldwide burden of cancer attributable to HPV by site, country and HPV type

3. Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995‐2016)

4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.Meeting (2008–2009): Lyon F International Agency for Research on Cancer World Health Organization. Biological Agents. International Agency for Research on Cancer.2012.

5. Global burden of cancers attributable to infections in 2012: a synthetic analysis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3